MARKET

OTLK

OTLK

Outlook Therapeutics Inc
NASDAQ
0.4210
-0.0131
-3.02%
Pre Market: 0.4220 +0.001 +0.24% 04:09 03/13 EDT
OPEN
0.4200
PREV CLOSE
0.4341
HIGH
0.4333
LOW
0.4100
VOLUME
1.09K
TURNOVER
0
52 WEEK HIGH
3.390
52 WEEK LOW
0.3801
MARKET CAP
34.97M
P/E (TTM)
-0.1553
1D
5D
1M
3M
1Y
5Y
1D
Outlook Therapeutics Announces Board Resignation and Size Reduction
TipRanks · 1d ago
Outlook Therapeutics director Julia A. Haller to step down effective March 10, 2026
Reuters · 1d ago
Outlook Therapeutics price target lowered to $6 from $10 at Ascendiant
TipRanks · 1d ago
Uniqure To Rally Around 92%? Here Are 10 Top Analyst Forecasts For Wednesday
Benzinga · 1d ago
Outlook Therapeutics Is Maintained at Buy by Ascendiant Capital
Dow Jones · 2d ago
Outlook Therapeutics Price Target Cut to $6.00/Share From $10.00 by Ascendiant Capital
Dow Jones · 2d ago
Ascendiant Capital Maintains Buy on Outlook Therapeutics, Lowers Price Target to $6
Benzinga · 2d ago
Outlook Therapeutics Shareholders Back Board, Pay, and Auditor
TipRanks · 2d ago
More
About OTLK
Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing ONS-5010/LYTENAVA (bevacizumab-gamma), an ophthalmic formulation of bevacizumab for use in retinal indications. It is advancing ONS-5010 / LYTENAVA (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab-vikg is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. ONS-5010/LYTENAVA, consisted of three clinical trials which it refers to as NORSE ONE, NORSE TWO and NORSE THREE.

Webull offers Outlook Therapeutics Inc stock information, including NASDAQ: OTLK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OTLK stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading OTLK stock methods without spending real money on the virtual paper trading platform.